Canakinumab treatment in children with familial Mediterranean fever: report from a single center
RHEUMATOLOGY INTERNATIONAL, cilt.38, sa.5, ss.879-885, 2018 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 38 Sayı: 5
- Basım Tarihi: 2018
- Doi Numarası: 10.1007/s00296-018-3993-5
- Dergi Adı: RHEUMATOLOGY INTERNATIONAL
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.879-885
- Anahtar Kelimeler: Amyloidosis, Canakinumab, Childhood, Familial Mediterranean fever, Uveitis, AUTOINFLAMMATORY DISEASES, SECONDARY AMYLOIDOSIS, CASE SERIES, COLCHICINE, INTERLEUKIN-1, THERAPY, UVEITIS, PATIENT, CHILDHOOD, ANAKINRA
- Ondokuz Mayıs Üniversitesi Adresli: Evet
Özet
Familial Mediterranean fever (FMF), the most common hereditary autoinflammatory disorder is characterized by recurrent episodes of fever, serositis, arthritis. The major long-term result is amyloidosis. Colchicine remains the principle of the treatment; it not only prevents the acute attacks but also prevents the long-term complications such as amyloidosis; 5-10% of the patients are unresponsive to treatment. Recently new therapeutic options as anti-interleukin 1 agents are successfully used for the patients who do not respond to colchicine treatment. In this study, we retrospectively evaluated 11 pediatric colchicine-resistant FMF patients who were treated with canakinumab. Three of the patients had amyloidosis and two had uveitis. Based on our results, we suggest that canakinumab may be a safe and effective therapy in patients who are resistant to colchicine and even in the patients with amyloidosis. We also suggest that canakinumab might be a safe option for the patients with uveitis.